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Nitric oxide (NO) is a diffusible radical gas that may serve as a chemical messenger or cytotoxic agent within the nervous system (1). Previous neurochemical studies indicate that NO is capable of stimulating the release of glutamate or other neurotransmitters (2-8). We (9) also reported using a microdialysis technique that local appli cation of sodium nitroprusside (SNP) and 8-bromo guanosine 3",5 cyclic monophosphate (8-bromo cGMP) caused an increase in serotonin (5-HT) release from the striatum of freely moving rats. NO-induced neurotrans mitter release may be mediated by its stimulatory action on cGMP formation, but the exact mechanism is not known. There is growing evidence that neurotrans mitters can be released not only by exocytosis but also through the membrane carriers responsible for trans mitter reuptake (10). The Ca 21_ or Na+-dependence of the NO effect suggests that NO evoked-neurotransmitter release is mediated by two distinct systems, a Ca t+-de pendent exocytosis and the reverse process of a Na+-de pendent carrier-mediated transporter (3, 5, 7, 11, 12) . In relation to the latter process, it was reported that NO donors inhibited the uptake of [3H]dopamine (13, 14) and
[3H]5-HT (14) into rat striatal synaptosomes. In contrast, Launay et al. (15) and Miller and Hoffman (16) showed that NO or cGMP increased 5-HT uptake in human platelets and rat basophilic leukemia cells, respectively. The effect of NO on 5-HT uptake in the brain has not been studied in detail. In this paper, we examined the effects of NO donors on the uptake of [3H]5-HT and the binding of the 5-HT transporter ligand [3H]paroxetine in rat cortical synaptosomes.
MATERIALS AND METHODS

Animals and preparation of synaptosomes
Thirty male Wistar rats (Shimizu Lab. Supplies Co., Ltd., Kyoto), weighing 100-200 g, were maintained un der controlled environmental conditions (22 ± 1 °C ; 12 -12 hr light-dark cycle, lights on at 08 hr 00 min food and water ad libitum). The rats were sacrificed and their brains dissected out. The cerebral cortex was homogenized in 10 vol. of sucrose buffer (0.32 M sucrose, 2 mM Tris HCI, pH 7.4) with a Teflon glass homogenizer. The homogenate was centrifuged at 1,000 x g for 10 min and the resulting supernatant centrifuged at 17,000 x g for 20 min. The final pellet was resuspended in the origi nal volume of homogenizing buffer and kept on ice. All experiments were performed according to the guiding principles for the care and use of laboratory animals ap proved by the Japanese Pharmacological Society.
[3H]5-HT uptake and [3HJparoxetine binding
[3H]5-HT uptake into the synaptosomes was measured as reported previously (17). A 50-pl aliquot of the crude synaptosome suspension was added to tubes containing 400 pl of incubation buffer (120 mM NaCI, 5 mM KCI, 1.2 mM MgC12, 2.5 mM CaC12, 10 mM glucose, 100 pM pargyline, 1 mM ascorbic acid and 20 mM Tris HCI, pH 7.4) aerated with 95 % 02 and 5 % CO2. The tubes were preincubated at 37C for 15 min in the presence or absence of drugs; then 50 p1 of [3H]5-HT (939.8 GBq/mmol) in concentrations ranging from 40 to 100 nM was added to each tube, followed by a 3-min incubation. Blank tubes representing nonspecific uptake were incu bated at 371C in the presence of 10 pM fluoxetine. Incu bation was terminated by the addition of 5 ml of ice-cold incubation buffer and subsequent filtration through Whatman GF/B filters. The filters were washed twice with 5 ml of ice-cold incubation buffer and dried, and the retained radioactivity was determined by liquid scintilla tion spectrometry. Net uptake was defined as the differ ence between the total and the nonspecific uptake. The maximum uptake rate and affinity constant were calcu lated from Linewaever-Burke plots.
For the [3H]paroxetine binding assay (18, 19) , the cerebral cortex was homogenized in 20 vol. of Tris buffer (120 mM NaCI, 5 mM KCl and 50 mM Tris HCI, pH 7.4) with a Polytron homogenizer. The homogenate was cen trifuged at 30,000 x g for 10 min. The pellet obtained was resuspended in the original volume of Tris buffer, homogenized and centrifuged again. The final pellet was resuspended in the original volume of Tris buffer and kept on ice. To each tube containing 1,240 pl of incuba tion buffer (in the presence or absence of 100 pM 5-HT for determination of total and nonspecific binding, respectively) was added 200 pl of the membrane suspen sion and 160 pl of [3H]paroxetine (832.5 GBq/mmol) in concentrations ranging from 0.015 to 2.0 nM. The final concentration of protein in the incubation tubes was about 750 pg. Tubes were incubated for 1 hr at 221C after which incubation was terminated by addition of 5 ml of ice-cold buffer and subsequent filtration through Whatman GF/B filters. The filters were washed 3 times Assay of ATP content Measurement of intrasynaptosomal ATP levels was carried out as described previously (20). In brief, the syn aptosomal suspension was centrifuged at 16,000 x g for 5 min, and the resulting pellet was resuspended in 0.5 M perchloric acid. The suspension was centrifuged at 16,000 x g for 5 min, and the supernatant obtained was neutralized by 3 M KOH/1.5 M triethanolamine. ATP in the extract was measured by the luciferase reaction, and the bioluminescence was detected with a Packard liquid scintillation counter (21).
Statistics
Statistical analyses were conducted by one-way ANOVA followed by Fisher's least significant difference (LSD) test, using statistical data analysis software (SPSS, Chicago, IL, USA). P values of 0.05 or less were considered statistically significant. 
RESULTS
Various NO donors such as NOC-7, NOC-12, SNP, SIN-1 and NO-CYS caused a dose-dependent inhibition of the uptake of [3H]5-HT into the cortical synaptosomes (Fig. 1) . NOC-7 and NO-CYS were more potent than SNP, NOC-12 and SIN-1 in inhibiting the uptake. NOC 12 at 0.1 mM increased rather than inhibited the uptake. K3Fe(CN)6 and K4Fe(CN)6 at 1 mM were without effect on
[3H]5-HT uptake (data not shown). The inhibitory effect of NO-CYS at 1 mM was attenuated by hemoglobin at 100 pM (Fig. 2) . A similar antagonism by hemoglobin was observed in the effect of SNP (data not shown). NO CYS at 100 300 pM decreased the uptake of [3H] 5-HT into the synaptosomes, and the reduced activity was in creased by subsequent washing of the synaptosomes (Fig.  3) . The effect of washing depended on the NO-CYS con centration used for treatment. In contrast to NO donors, the cGMP agonist 8-bromo cGMP at 1 pM -1 mM did not affect the uptake of [3H]5-HT into the synaptosomes (Fig. 4) . Kinetic analysis showed that NO-CYS at 100 pM decreased the maximal uptake without changing the affinity for 5-HT (Fig. 5) The effect of SNP and NO-CYS on the synaptosomal ATP content was examined (Fig. 7) . At 100 pM, SNP, IAA and NaCN, but not NO-CYS, decreased the ATP content, whereas only the NO donors SNP and NO-CYS decreased the uptake of [3H]5-HT into the synaptosomes. At 1 mM, all these drugs decreased the ATP content, whereas IAA did not affect the uptake of [3H]5-HT. 
DISCUSSION
Previous studies suggest that NO evoked-neurotran smitter release is mediated by two distinct systems, a Cat+-dependent exocytosis and the reverse 5-HT trans port mechanism (3, 5, 7, 11, 12) . Pogun et al. (14) showed that SNP inhibits the uptake of [3H]5-HT into the striatal synaptosomes. In this paper, we confirmed the inhibi tory effect of SNP on the uptake of [3H]5-HT in rat cor tical synaptosomes and further studied the mechanism for inhibition. NO donors such as NO-CYS, NOC-7, SNP, SIN-1 and NOC-12 inhibited the uptake of [3H]5-HT into the synaptosomes. Furthermore, reduced hemoglobin, which binds NO, attenuated the inhibitory effect of NO CYS, but K3Fe(CN)6 and K4Fe(CN)6, compounds similar to SNP in chemical structure but which do not release NO, were without effect on uptake. These findings indi cate that the uptake of [3H]5-HT, like [3H]dopamine (13, 14) , is lowered by NO. The partial protection by hemoglobin may be explained by the high concentration of NO-CYS compared with hemoglobin. Alternatively, NO-CYS at the high concentration is considered to have an NO-unrelated effect on 5-HT uptake, although the de tails are not known. Kinetic study showed that NO-CYS caused a decrease in Vmax without a significant change in Km value. In addition, the binding experiment of [3H] paroxetine, a ligand for 5-HT transporter, indicates that NO-CYS does not affect the 5-HT transporter. That is, NO does not interact directly with the paroxetine recog nition site. The similar observation was reported in the NO-CYS-induced decrease in [3H]dopamine uptake: NO CYS decreased the capacity of the dopamine transporter without having a significant effect on the affinity, and it had no effect on [3H]mazindol binding (13).
The potencies of the NO donors used here were in this order: NO-CYS, NOC-7 > SNP, SIN-1 > NOC-12. The difference in potency among NO donors may be due to that in NO production, since NO liberation is more rapid in NOC-7 than in . NO can occur in free radical form (NO'), as a nitrosonium cation (NO+), or as a nitroxyl anion (NO-), and NO' can react with super oxide to form peroxynitrite, a highly toxic compound. Ohkuma et al. (24 26) reported that NO donor-evoked re lease of neurotransmitters might be due to the formation of peroxynitrite. In contrast, the present finding that the effects of NO-CYS and NOC-7 are more potent than that of SIN-1, a peroxynitrite donor (27), suggests that the inhibition of 5-HT uptake by NO donors may be due to NO rather than peroxynitrite, although it remains to be determined if superoxide is involved in the NO effect on 5-HT uptake.
The decreased activity of 5-HT uptake by NO-CYS treatment was partially reversed by washing the synapto somes. The reversibility suggests that NO may be a phys iological regulator of 5-HT uptake. One target molecule of NO is the soluble guanylyl cyclase, and the 5-HT transporter has multiple consensus sites for various pro tein kinases (16). NO-induced cGMP would activate cGMP-dependent protein kinase which would then phos phorylate either the 5-HT transporter directly or some other closely associated protein. In this relation, the in crease in 5-HT transport by cGMP was shown in human platelets (15) and rat basophilic leukemia cells (16). Fur thermore, Pogun et al. (14) reported in their preliminary experiments that dibutyryl cGMP inhibited [3H]dopa mine uptake. However, the present study showed that 8 bromo-cGMP did not affect [3H]5-HT uptake. Then, it is unlikely that NO-induced inhibition of 5-HT transport in the brain is due to its action on the guanylate cy clase/cGMP system. This finding also suggests that the reverse 5-HT transport mechanism is not involved in cGMP-induced facilitation of in vivo 5-HT release. The autoribosylation of glyceraldehyde-3-phosphate dehydro genase, which leads to a loss of its glycolytic enzyme activity, may be an alternative mechanism for the NO induced decrease in 5-HT uptake (28). However, the present study showed that 5-HT uptake and cellular ATP content were not coordinately altered by metabolic inhi bitors and NO donors. Thus, it is unlikely that the NO induced decrease in 5-HT uptake is due to a general metabolic mechanism of NO. Further studies are required to clarify biochemical interactions responsible for the NO-induced decrease in 5-HT uptake.
In conclusion, the present study shows that NO inhibits 5-HT uptake into the synaptosomes through a cGMP independent mechanism. This suggests that NO-induced 5-HT release is in part mediated by the reverse 5-HT transport mechanism and supports the hypothesis that
